Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Safety, antiviral effect and pharmacokinetics of BI 207127 in combination with BI 201335 and with ribavirin for 4 weeks (Part 1) and with or without ribavirin for 16, 28 or 40 weeks (Part 2) in patients with chronic HCV genotype 1 infection (randomized, open label, Phase Ib/II)

Next Previous
Trial Profile

Safety, antiviral effect and pharmacokinetics of BI 207127 in combination with BI 201335 and with ribavirin for 4 weeks (Part 1) and with or without ribavirin for 16, 28 or 40 weeks (Part 2) in patients with chronic HCV genotype 1 infection (randomized, open label, Phase Ib/II)

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 21 Dec 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Deleobuvir (Primary) ; Faldaprevir (Primary) ; Interferon alpha-2a; Ribavirin
  • Indications Hepatitis C
  • Focus Pharmacogenomic; Therapeutic Use
  • Acronyms SOUND-C1; SOUND-C2; SOUND-C3
  • Sponsors Boehringer Ingelheim Pharmaceuticals

Most Recent Events

  • 17 Nov 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
  • 13 Apr 2014 Pharmacogenomic analysis presented at the 49th Annual Meeting of the European Association for the Study of the Liver.
  • 02 Apr 2014 As per the ClinicalTrials.gov record, planned end date changed from 1 Dec 2015 to 1 Oct 2014.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top